Redeye returns following the conference call and chat with management with more flesh on the bones regarding the next steps after the announced FDA approval. We anticipate the first CERAMENT G sales to be recorded in the latter part of H2’22E, and our view on a quick sales ramp-up is further cemented. We raise our Base Case to SEK 77 (70).
LÄS MER
